Analysis of changes in adipose tissue of patients infected with HIV and lipoatrophy treated with nucleoside thymidine, after a switch to monotherapy with lopinavir/ritonavir [Analisis de Los Cambios en el Tejido Adiposo de Pacientes Con infeccion VIH y Lipoatrofia en Tratamiento Con analogos de nucleosidos timidinicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir]

Trial Profile

Analysis of changes in adipose tissue of patients infected with HIV and lipoatrophy treated with nucleoside thymidine, after a switch to monotherapy with lopinavir/ritonavir [Analisis de Los Cambios en el Tejido Adiposo de Pacientes Con infeccion VIH y Lipoatrofia en Tratamiento Con analogos de nucleosidos timidinicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir]

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2013

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Lamivudine/zidovudine/abacavir
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms BIOKAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Dec 2012 last checked against European Clinical Trials database.
    • 10 Dec 2012 Status changed from suspended to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top